Peptides for Muscle Growth Research: A Canadian Guide
Few areas of peptide science draw as much laboratory attention as the growth-hormone axis. A cluster of research compounds sits around this single pathway, and understanding how they relate makes the published literature far easier to read. This Canadian guide sorts those compounds into families, sketches the biology that connects them, and notes where each one appears in cell and animal research. Everything below describes what laboratories examine in preclinical models. Nothing here is a training method, a body-composition claim, or a protocol for use in people.
The GH to IGF-1 axis in one view
Most of these compounds cluster around a single signalling cascade. The hypothalamus releases growth-hormone-releasing hormone, or GHRH, which prompts the pituitary to secrete growth hormone, or GH. GH then travels to the liver and peripheral tissues, where it drives production of insulin-like growth factor 1, or IGF-1. IGF-1 is the downstream messenger that much of GH's tissue-level activity is attributed to, including the effects on protein synthesis and cell proliferation studied in myoblast and fibroblast cultures. A second control layer runs through ghrelin, a stomach-derived hormone that binds the growth-hormone secretagogue receptor, or GHS-R, and amplifies GH pulses. The research peptides in this space each pull one of a few levers - they mimic GHRH, mimic ghrelin, supply IGF-1 activity directly, or supply the GH molecule itself. Identifying which lever a compound pulls is the quickest way to place it in the literature.
| Compound | Class | Research focus |
|---|---|---|
| Ipamorelin | GHS-R agonist (ghrelin mimetic) | Selective GH release studied with minimal cortisol or prolactin effect |
| CJC-1295 with Ipamorelin | GHRH analog plus secretagogue | Dual-receptor GH-release models examined as a pair |
| GHRP-2 | Growth-hormone-releasing peptide | GH pulse amplitude and appetite signalling |
| Tesamorelin | Stabilized GHRH analog | Visceral adipose tissue and metabolic endpoints |
| IGF-1 LR3 | Long-acting IGF-1 analog | Cell proliferation and IGFBP binding studies |
| PEG-MGF | IGF-1 splice variant (pegylated) | Satellite-cell activation and muscle-repair models |
| HGH 191aa | Recombinant growth hormone | The GH molecule itself in reference research |
| BPC-157 | Cytoprotective peptide | Tendon, ligament, and gut-lining repair models |
| TB-500 | Actin-regulating fragment | Cell migration, angiogenesis, and tissue remodeling |
GH secretagogues and GHRH analogs
Ipamorelin is a pentapeptide and a selective agonist at the growth-hormone secretagogue receptor, meaning it acts as a ghrelin mimetic. Research characterizes it as prompting GH release while leaving cortisol and prolactin largely unchanged, which is why it appears so often in studies comparing secretagogue selectivity. CJC-1295 with Ipamorelin pairs a GHRH analog with that ghrelin-mimetic secretagogue. The two act on different receptors, so their GH-releasing behaviour is frequently examined together in the literature rather than in isolation. GHRP-2 is another growth-hormone-releasing peptide and GHS-R agonist, studied for producing pronounced GH pulses and for its documented signalling toward appetite pathways. Tesamorelin is a stabilized 44-amino-acid GHRH analog; among this group it is the compound most examined in connection with visceral adipose tissue and lipid endpoints in the research record.
The IGF-1 family
If the secretagogues act upstream, the IGF-1 family acts at the downstream end of the same axis. IGF-1 LR3 is a modified analog, the Long Arg3 variant, engineered to bind IGF binding proteins weakly. That reduced binding lengthens its measured half-life in experimental settings, and it is studied for effects on cell proliferation and protein synthesis in culture. PEG-MGF is built around mechano growth factor, an IGF-1 splice variant that appears in the research on mechanical loading and muscle repair. The pegylated form is studied because polyethylene glycol attachment extends the window over which the molecule remains active in a preparation. MGF shows up frequently in satellite-cell and myogenesis literature.
Recombinant growth hormone
HGH 191aa somatropin is recombinant human growth hormone expressed as the full 191-amino-acid sequence. Unlike the secretagogues, which coax the pituitary into releasing more of its own GH, this is the GH molecule itself. In research it serves as the reference point for the entire axis, the endpoint that GHRH analogs and ghrelin mimetics are ultimately compared against when investigators measure downstream IGF-1 output.
Repair peptides studied alongside
Two further compounds appear so often next to the GH-axis peptides that a survey would feel incomplete without them. BPC-157, the body protection compound, is a pentadecapeptide derived from a gastric protein and studied in tendon, ligament, muscle, and gut-lining models for its cytoprotective and angiogenic signalling. TB-500 is a synthetic fragment related to thymosin beta-4, examined for its role in actin regulation, cell migration, and blood-vessel formation. Neither is a growth-hormone compound, but connective-tissue and recovery research routinely places them in the same experimental frame as the axis peptides above.
Reading the group as a system
The value of grouping these compounds is that the literature rarely studies them in a vacuum. A GHRH analog and a ghrelin mimetic are compared for how their receptors interact; an IGF-1 analog is measured against the GH that would normally drive IGF-1 production; repair peptides are folded in wherever tissue remodeling is the endpoint. For a fuller treatment of the upstream biology, see our overview of the growth-hormone research peptides and the companion piece on research peptides studied on the growth-hormone axis. Every compound named here is available for research purposes through our store, and each product page carries its own certificate of analysis and handling notes.
Research use only. This article is educational and is not medical, legal, or financial advice. The compounds discussed are not approved for human or veterinary use, consumption, or therapeutic application.